[Intraarterial chemo-embolization with adriamycin containing albumin microspheres]

Area of Science:

• Oncology
• Interventional Radiology
• Drug Delivery Systems

Background:

• Inflammatory breast cancer and recurrent breast cancers with liver metastasis present significant treatment challenges.
• Intraarterial infusion chemoembolization offers a localized approach to deliver chemotherapy directly to tumors.
• Albumin microspheres loaded with adriamycin (ADM-ms) represent an advanced drug delivery system for targeted cancer therapy.

Observation:

• The study involved 2 cases of inflammatory breast cancer and 3 cases of recurrent breast cancers with liver metastasis.
• ADM-ms was administered via intraarterial infusion into the internal mammary artery and lateral thoracic artery for primary breast tumors.
• For liver metastases, ADM-ms was injected into the hepatic artery.

Findings:

• Intraarterial chemoembolization with ADM-ms resulted in a remarkable reduction in primary tumor size.
• Histological examination revealed extensive central fibrosis and degenerated cancer cells in the periphery of resected primary tumors.
• Effective tumor size reduction was observed in one of the liver metastasis cases; local side effects included skin disturbances, with no serious systemic toxicity reported.

Implications:

• Intraarterial chemoembolization using ADM-ms demonstrates potential as a neoadjuvant therapy for inoperable inflammatory breast cancer.
• This localized treatment approach may improve outcomes for patients with advanced or recurrent breast cancer.
• Further research is warranted to optimize ADM-ms chemoembolization for breast cancer treatment and evaluate its long-term efficacy.